来自MSN1 个月
Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months
MONDAY, Dec. 23, 2024 (HealthDay News) -- For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib ...